ALK (anaplastic lymphoma kinase): The ALK gene makes an ALK protein, which may be involved in signaling cell growth. Mutations of the ALK gene have been associated with certain types of cancer, …

May 8, 2024 · FDA has approved alectinib (Alecensa) as an adjuvant therapy for people with non-small cell lung cancer (NSCLC) who have ALK-positive tumors.

Aug 2, 2024 · Alecensa is also used as an adjuvant treatment in adult patients following tumor resection of (ALK)-positive non-small cell lung cancer (NSCLC) when tumors ≥ 4 cm or node positive, as …

On April 18, 2024, the Food and Drug Administration approved alectinib (Alecensa, Genentech, Inc.) for adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK ...

Sep 4, 2019 · ALECENSA (alectinib) Fact Sheet ALECENSA® (alectinib) Fact Sheet ALECENSA is a kinase inhibitor approved for the treatment of people with anaplastic lymphoma kinase (ALK)-positive …

Alecensa (alectinib) is a medicine used for treating certain lung cancers. Alecensa is used to treat non-small-cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.

Oct 20, 2023 · Results of the ALINA clinical trial confirm superiority of Alecensa over chemotherapy for treatment of ALK mutated early stage NSCLC establishing Alecensa as the standard initial treatment …

Apr 10, 2024 · Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of …

Who is ALECENSA for? ALECENSA is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene: as …

The researchers added that this study reinforces the need for implementation of biomarker testing for ALK alterations, across all stages of NSCLC. Alectinib in Resected ALK-Positive Non–Small-Cell …